Ivabradina Tarbis

Ivabradine, the active ingredient in Ivabradina Tarbis, is a If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is used to manage chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradina Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to lower heart rate, benefiting conditions where heart‑rate control improves outcomes.

- Chronic stable angina: decreases frequency of angina episodes by lowering myocardial oxygen demand. - Heart failure with reduced ejection fraction: improves symptoms and reduces hospitalisations by maintaining target heart rate. - Inadequate heart‑rate control despite optimal therapy: provides additional rate reduction when beta‑blockers are insufficient or not tolerated.

Ivabradine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: heart rate slower than intended. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Fatigue or weakness. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical attention. - Atrial fibrillation or other arrhythmias. - Severe hypotension. - Symptomatic heart block. - Acute coronary syndrome (rare). - Allergic skin reactions.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

- Heart‑rate monitoring: ensure resting rate remains above 50 bpm. - Hepatic impairment: use with caution in moderate to severe liver disease. - Sick sinus syndrome or AV block: contraindicated unless a pacemaker is present. - Concomitant bradycardic agents: avoid or adjust dose when combined with beta‑blockers or calcium‑channel blockers. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Ivabradine can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine plasma levels. - Other heart‑rate‑lowering agents (beta‑blockers, diltiazem, verapamil): risk of excessive bradycardia. - Certain anti‑arrhythmic drugs (e.g., amiodarone): can potentiate bradycardic effects.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may require dose adjustment. - Diuretics and antihypertensives: monitor blood pressure and electrolytes. - St. John’s wort (CYP3A4 inducer): may reduce ivabradine effectiveness.